Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RmAbSynO2-scFv8D3
- Development stage
- Preclinical
- Lead developer
- Uppsala University
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intraperitoneal
01
Overview
RmAbSynO2-scFv8D3 is a brain-penetrating bispecific antibody designed for the treatment of Parkinson's disease and other alpha-synucleinopathies. It consists of a monoclonal antibody (RmAbSynO2) that selectively targets aggregated alpha-synuclein (αSYN) fused to a single-chain variable fragment (scFv8D3) that binds to the transferrin receptor (TfR). By utilizing receptor-mediated transcytosis via the TfR, the antibody can effectively cross the blood-brain barrier (BBB), achieving significantly higher brain concentrations than standard antibodies. In preclinical models, it has demonstrated the ability to reduce soluble aggregated αSYN pathology in the cortex and midbrain, suggesting that facilitated brain uptake can improve the therapeutic efficacy of αSYN-targeted immunotherapies.
02
Targets
aggregated α-syn (Alpha-synuclein (α-syn))TFRC (Transferrin Receptor)
Beyond the preview
Go deeper on RmAbSynO2-scFv8D3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RmAbSynO2-scFv8D3.